Evidence map›Paper›PMID 34850319›Full record

ArticleIrish journal of medical science2022

Evaluation of ECLIA antigen detection tests as screening methods for COVID-19 in comparison with molecular analysis.

Olga Kolesova, Flaminia Tomassetti, Paola Cerini, Davide Finucci, Giordano Turchetti, Francesca Capogreco, Sergio Bernardini, Graziella Calugi, Massimo Pieri

Open access · bronzeAbstract read
In one paragraph

Article in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Olga Kolesova *Department of Public Health and Infectious Diseases, University of Rome, La Sapienza, Rome, Italy.
Flaminia Tomassetti *Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Paola CeriniLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy.
Davide FinucciLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy.
Giordano TurchettiLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy.
Francesca CapogrecoLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy.
Sergio BernardiniDepartment of Experimental Medicine, University of Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Graziella CalugiLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy.
Massimo PieriLifebrain Srl, Guidonia Montecelio, Viale Roma 190/A, Rome, Italy. massimo.pieri@uniroma2.it.ORCID http://orcid.org/0000-0002-3463-0268
University of Rome Tor Vergata · ITSapienza University of Rome · ITUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData from literature shows that antigen tests are rapid and helpful tools for diagnosis of COVID-19.

aimThis work aimed to evaluate the performances of the Elecsys SARS-CoV-2 Antigen test, in comparison to RT-qPCR, the gold standard.

methodsA total of 110 swabs were tested; according to rRT-PCR, 76 were positive, and 34 were negative. The swabs were processed by Elecsys SARS CoV 2 Antigen assay (Roche Diagnostics GmbH, Mannheim, Germany), an electrochemiluminescence immunoassay (ECLIA).

resultsIn a first evaluation, the overall sensitivity and specificity were 85% and 100%, respectively. It was noted that most of the discordant cases had cycle threshold (Ct) values > 28. Therefore, it was assumed a new measure to evaluate sensitivity and specificity, then samples with Ct values < 28 were selected. In this way, it was achieved a Ct < 28 sensitivity of 94%. The level of agreement between the two tests was 89. 1% with κ value of 0.77 for total data and 95.9% with κ value of 0.95 for samples with < 28 Ct. The antigen test performs well in the presence of high viral loads, whereas lower levels are missed.

conclusionsThe comparison data obtained in this study support that this method seems a proper approach for rapid screening of patients with high SARS-CoV-2 viral load; however, the rate of sensitivity is highly Ct-dependent.

Indexed as

COVID-19COVID-19 TestingHumansRNA, ViralSARS-CoV-2Sensitivity and SpecificityRNA, ViralAntigen testCOVID-19Diagnostic methodologyMolecular analysisSARS-CoV-2

Identifiers

PMID34850319
PMCPMC8631556
OpenAlexW3216728167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.